Best Peptide Medicines for Weight Loss
Start with the reason for treatment and the exact form you’re considering. General weight care, treatment for a specific cause of obesity, and participation in a trial are different decisions.
Read moreShow less
The best access route depends on the medicine you and your clinician choose. We compare labeled uses and verified access for each form, with trial evidence and research-only listings clearly marked.
Sources reviewed
Our medicine picks by need
Best-supported for greater weight loss in this head-to-head trial
Zepbound injection
FDA-approved for the specified use
Over 72 weeks, tirzepatide produced greater average weight loss than semaglutide at the highest doses participants could tolerate in adults with obesity without diabetes.
The trial compared specific injection regimens. It did not test the 7.2 mg Wegovy injection or Wegovy tablets.
Best fit if you want an FDA-approved peptide pill
Wegovy tablets
FDA-approved for the specified use
This semaglutide tablet has a labeled adult weight-management use and a placebo-controlled trial of the 25 mg tablet regimen.
A separate study and prescribing instructions apply. The trial does not show that the tablet works as well as a particular injection.
Best-supported peptide option for diagnosed acquired hypothalamic obesity
Imcivree injection
FDA-approved for the specified use
Imcivree has a specific FDA-approved use for patients aged 4 and older with acquired hypothalamic obesity. A randomized trial directly studied that condition.
This pick is specific to the diagnosed cause. It does not apply to general obesity or grade the medicine for other labeled diagnoses.
Compare weight-management medicines
Start with the use that matches your situation. Each entry shows what the FDA label or the research covers.
Wegovy injection
Semaglutide · GLP-1
FDA-approved for eligible patients
Weekly injection for long-term weight reduction and maintenance in eligible adults and certain adolescents. Confirm the prescribed pen and strength.
Wegovy tablets
Semaglutide · GLP-1
FDA-approved for eligible adults
Daily tablet for long-term weight reduction and maintenance in eligible adults. The tablet and injection have separate instructions and evidence.
Wegovy HD 7.2 mg injection
Semaglutide · GLP-1
FDA-approved for eligible adults
A distinct higher-strength pen for eligible adults under the labeled conditions. The 2.4 mg pen’s prices, provider picks and continuation results do not apply to this offer.
Zepbound
Tirzepatide · GIP and GLP-1
FDA-approved for eligible adults
The label includes long-term weight reduction and maintenance for adults who meet its criteria.
Imcivree
Setmelanotide · MC4 receptor agonist
FDA-approved for specific causes of obesity
The label covers acquired hypothalamic obesity and certain genetic conditions. Eligibility depends on the diagnosed cause and age.
Saxenda
Liraglutide · GLP-1
FDA-approved for eligible patients
The label covers chronic weight management for eligible adults and certain adolescents. Compare the actual prescription and access route.
Generic liraglutide for weight management
Liraglutide · GLP-1
FDA-approved generic for eligible patients
FDA lists a generic that references Saxenda. Ask the pharmacy to confirm the indicated product and the box of pens it can supply.
Ozempic when discussed for primary weight loss
Semaglutide · GLP-1
FDA-approved medicine · weight loss is off-label
Its injection label lists type 2 diabetes and certain heart and kidney uses. Ask what evidence and coverage apply to the specific prescription you were offered.
Compounded weight medicine
A pharmacy preparation for a specific patient need
Compounded · no FDA approval of the finished product
A clinician and pharmacy need to identify the reason for compounding and the exact preparation. An ingredient name or brand trial does not verify a particular compounded product.
Cagrilintide
Long-acting amylin analogue
Investigational · no FDA approval for weight management
A phase 2 study tested cagrilintide alone for 26 weeks in adults with overweight or obesity. Weight fell more with cagrilintide than with placebo.
Petrelintide
Human amylin analogue
Investigational · no FDA approval for weight management
ZUPREME 1, a randomized phase 2 trial in adults with overweight or obesity, reported greater weight reduction with petrelintide than with placebo at 42 weeks.
Eloralintide
Selective amylin receptor agonist
Investigational · no FDA approval for weight management
A randomized phase 2 study in adults with obesity or overweight without type 2 diabetes found greater weight reduction with eloralintide than with placebo at 48 weeks.
Retatrutide
GLP-1, GIP and glucagon
Investigational · no FDA approval for weight management
The phase 3 TRIUMPH-1 obesity trial reported greater weight reduction with retatrutide than with placebo. The results apply to the study preparation and population.
CagriSema
Cagrilintide and semaglutide · amylin and GLP-1
Investigational combination
REDEFINE 1 studied this combination separately from either component alone. Approval of a semaglutide product does not extend to this combination.
AOD-9604
Growth hormone fragment
Research only · No FDA-approved weight-loss product
The FDA briefing describes a large obesity study that found no significant weight-loss difference versus placebo at 12 weeks. That study does not verify finished products sold under this name.
Open research notice
For research use only
Products sold for laboratory research aren’t intended for use in people. Continuing opens the FDA evidence review.
Continue for research
Looking for Foundayo? It is an FDA-approved oral small-molecule medicine for eligible adults. Read the Foundayo guide.
Plan your next step
See a problem or outdated information? Tell us.